About CareDx
CareDx is a publicly listed company based in Brisbane (United States) founded in 1998. Medical solutions for transplant patients are developed and provided. CareDx has raised $138.21 million across 19 funding rounds from investors including SVB, Intel and Kleiner Perkins. The company has 650 employees. CareDx has completed 9 acquisitions, including Allenex, BFS Molecular and MedActionPlan. Its website caredx.com draws about 15 thousand monthly visits. CareDx offers products and services including AlloSure, AlloSeq, and AlloCare. Its focus areas include Life Sciences, Transplant Medicine and Drugs. Its legal entity is CareDx, Inc. Its competitors include Tonix Pharma, Eledon and Aditx Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
CareDx was founded in 1998 and is headquartered in Brisbane, United States. Precision medicine solutions are offered by the company in the transplant healthcare sector, encompassing products, testing services, and digital tools for pre- and post-transplant care. AlloSure, a non-invasive donor-derived cell-free DNA test, is utilized for detecting kidney injury and rejection in kidney transplant patients. Additional offerings include solutions for heart transplants, laboratory products, and the RemoTraC monitoring service.
- Headquarters Brisbane, United States
- Employees 650
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website caredx.com
- Social LinkedIn X Facebook Instagram
- Legal Name Caredx, Inc.
- Annual Revenue$379.81 M (USD)13.79as on Dec 31, 2025
- Net Profit-$21.35 M (USD)-140.64as on Dec 31, 2025
- EBITDA-$1.71 M (USD)94.91as on Dec 31, 2025
- Total Equity Funding$138.21M (USD)
in 19 rounds
- Latest Funding Round$15M (USD), Debt – Conventional
Mar 2018
- InvestorsSVB
& 15 more
- Employee Count650
- Investments & AcquisitionsAllenex
& 8 more
Products & Services of CareDx
CareDx offers a comprehensive portfolio of products and services, including AlloSure, AlloSeq, and AlloCare.
Monitors kidney transplant health through cfDNA analysis
Facilitates organ matching with advanced genetic testing
App for managing transplant patient medications and health
Funding Insights of CareDx
CareDx has successfully raised a total of $138.21M across 19 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $15 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $138.21M
- Total Rounds 19
- Last Round Debt – Conventional — $15M
- First Round $14.75M
(Apr 2004)
- Investors Count 16
Latest 10 of 19 funding rounds of CareDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $15M | Debt – Conventional | – | – | |
| Mar 2017 | $28M | Post-IPO | – | – | – |
| Jul 2016 | $36.8M | Post-IPO | – | – | – |
| Apr 2016 | $22.17M | Post-IPO | – | – | – |
| Sep 2013 | $267,693 | Grant | – | – | |
| Sep 2012 | $15M | Debt – Conventional | – | – | |
| Sep 2012 | $15M | Debt – Conventional | – | – | |
| Nov 2011 | $2.16M | Debt – Conventional | – | – | – |
| Oct 2011 | $2.16M | Series G | – | – | – |
| Jan 2011 | $12.5M | Grant | – | – |
16 investors in total: 16 institutional.
Investors in CareDx
CareDx has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Intel and Kleiner Perkins.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Growth stage tech & life sciences focused VC firm funding companies in the US | icp.com | Menlo Park, United States | ||
US investment opportunities are targeted from San Francisco. | dagllc.com | San Francisco, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Investment in technology startups focusing on compute, AI, and related innovations. | intelcapital.com | |||
Multiple sectors are invested in by this private equity firm. | gecapital.ca | |||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for CareDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CareDx
15 people are tracked at CareDx (12 in leadership, 1 in board & advisors, 2 in team); the tracked headcount is 650.
| Name | Role | Group |
|---|---|---|
Jarrod Borkat | SVP, Head of Marketing & Portfolio Operations | Leadership |
Pauline Callinan | VP, Business Development | Leadership |
Ashish Kothari | VP, Medical Affairs | Leadership |
Reginald Seeto | President & CEO | Leadership |
Stacey Follon | SVP, Head of Human Resources | Leadership |
Abraham Ronai | Chief Administrative & Legal Officer & Secretary | Leadership |
Abhishek Jain | Chief Financial Officer | Leadership |
Alexander L. Johnson | President of Patient & Testing Services | Leadership |
Srini Srinivas | Chief Medical Officer | Leadership |
Mickey Kim | SVP, Corporate Development & Head Of Global Product | Leadership |
Kashif Rathore | Chief of Patient & Digital Solutions | Leadership |
Kim Clark-Langone | VP, New Technology Development | Leadership |
Hannah Valantine | Director | Board & advisors |
Marco Scheller | SVP, Clinical Operations | Team |
Jeffrey A. Novack | General Counsel | Team |
Complete people profiles for CareDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CareDx
CareDx is a publicly listed company on the NASDAQ with ticker symbol CDNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jul 2014
- Listed onNASDAQ: CDNA
- Listed entityCareDx, Inc.
- Exchange sectorHealth technology
- ISINUS14167L1035
- Share price$65.43 (+3.66% on the day) · 2026-10-13
- Market capitalisation$3.38B
- Price to earnings31.5
- EPS (diluted, trailing year)$2.07
- Volume (last session)1,498,259
Financials of CareDx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $379.8M | -$21.4M | -$1.7M |
| 2024 | $333.8M | $52.5M | -$33.5M |
| 2023 | $280.3M | -$190.3M | -$82.1M |
| 2022 | $321.8M | -$76.6M | -$61.2M |
| 2021 | $296.4M | -$30.7M | -$17.5M |
Detailed financial statements for CareDx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CareDx
CareDx has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Allenex, BFS Molecular and MedActionPlan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Blood tests for early cancer detection are provided. | naveris.com | Waltham, United States | 2017 | Apr 2026 | $160M | |
Organ transplantation management software is provided for healthcare organizations. | gomedigo.io | Baltimore, United States | 2020 | Jul 2023 | •••• | |
Provider of mobile app for medication management | medactionplan.com | Peapack, United States | 2001 | Nov 2021 | •••• | |
Mobile app for medication adherence | transplanthero.com | New York, United States | 2014 | Jun 2021 | •••• | |
Developer of diagnostics for post-transplantation care | bfsmolecular.com | Budapest, Hungary | 2017 | Mar 2021 | •••• | |
Patient and practice management software for healthcare providers is supplied. | transchart.com | Columbus, United States | 2002 | Jan 2021 | •••• | |
Leadership consulting services are provided by XynManagement to organizations. | xynmanagement.com | Boerne, United States | 2012 | Aug 2019 | •••• | |
Transplant patients are tracked and managed via a web-based platform. | ottr.com | Omaha, United States | 1993 | Apr 2019 | $16M | |
Transplantation diagnostic kits for matching and rejection prevention are developed. | allenex.com | Stockholm, Sweden | 1998 | Dec 2015 | •••• |
Complete acquisition details for CareDx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CareDx
13 dated milestones of CareDx across 28 years, from founding to its latest funding, stage changes and deals.
- Founded CareDx is founded.
- Funding First funding round of $14.8M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Allenex.
- Funding Latest funding round, Debt – Conventional, of $15.0M.
- Acquisition Acquires OTTR.
- Acquisition Acquires XynManagement.
- Acquisition Acquires TransChart.
- Acquisition Acquires BFS Molecular.
- Acquisition Acquires Transplant Hero.
- Acquisition Acquires MedActionPlan.
- Acquisition Acquires MediGO.
- Acquisition Acquires Naveris.
Competitors of CareDx
CareDx has 3 listed competitors in our database, 3 of them funded. They include Tonix Pharma, Eledon and Aditx Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| eledon.com | 2004 | Irvine, United States | $1.89M | 17 | Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | |
| aditxt.com | 2017 | Loma Linda, United States | $109,800 | 61 | Immune monitoring solutions are provided to the medical community. |
Detailed competitors of CareDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CareDx
The website of CareDx (caredx.com) receives about 15.3K visits a month.
- Monthly visits15.3K
▼ 4.2% vs previous month
Websites whose visitors overlap most with CareDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medactionplan.com | 100% | 4.4K | #4,123,287 | View details | |
| childrensmn.org | 54% | 275.5K | #163,951 | View details | |
| ecri.org | 54% | 104.8K | #312,846 | View details |
Top companies in Transplant Medicine
3 companies that operate in the same segment as CareDx (Transplant Medicine) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caredx
Complete news archive for CareDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CareDx
CareDx was founded in 1998 and raised its 1st funding round 6 years after it was founded.
CareDx is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
CareDx is a funded company, having raised a total of $138.21M across 19 funding rounds to date. The company's 1st funding round was a Grant of $12.5M, raised on Apr 2004.
CareDx has 650 employees.
Annual revenue of CareDx is $379.81M as on Dec 31, 2025.
CareDx was founded in 1998 and is headquartered in Brisbane, United States. Precision medicine solutions are offered by the company in the transplant healthcare sector, encompassing products, testing services, and digital tools for pre- and post-transplant care. AlloSure, a non-invasive donor-derived cell-free DNA test, is utilized for detecting kidney injury and rejection in kidney transplant patients. Additional offerings include solutions for heart transplants, laboratory products, and the RemoTraC monitoring service.
CareDx's top competitors include Tonix Pharma, Eledon and Aditx Therapeutics.
CareDx offers AlloSure, AlloSeq, and AlloCare.
Yes, CareDx is publicly traded on NASDAQ under the ticker symbol CDNA.
CareDx has made 9 acquisitions, including Allenex, BFS Molecular, and MedActionPlan.
CareDx has 16 investors. Key investors include SVB, Intel, Kleiner Perkins, Credit Suisse, and TPG.
CareDx operates through Caredx, Inc.